17 terminated. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Terminated 17 |
| Phase 2 | 2 | Terminated 2 |
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 378 | 2022-07-07 | 2025-04-04 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 258 | 2021-07-01 | 2025-02-05 |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia Dociparstat, Control - Acute Myeloid Leukemia | Phase 3 | Terminated | Jazz Pharmaceuticals | 9 | 2021-04-30 | 2024-04-15 |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib - Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital Heidelberg | 28 | 2021-04-01 | 2022-07-01 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Uproleselan, Placebo - Acute Myeloid Leukemia | Phase 3 | Terminated | GlycoMimetics Incorporated | 388 | 2018-10-15 | 2024-07-29 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Pracinostat, Placebos, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Helsinn Healthcare SA | 406 | 2017-06-23 | 2022-03-10 |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations chemotherapy (Mitoxantrone, Cytarabine), Placebo, Crenolanib - Acute Myeloid Leukemia | Phase 3 | Terminated | University of Ulm | 9 | 2016-11-17 | 2021-10-06 |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 33A, placebo, azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Seagen Inc. | 240 | 2016-05-01 | 2018-12-12 |
| Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior Cytarabine consolidation, Allogeneic transplant - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 10 | 2013-12-01 | 2018-08-14 |
| HCT Versus CT in Elderly AML hematopoietic cell transplantation, Non-Transplant treatment approach for consolidation - Acute Myeloid Leukemia | Phase 3 | Terminated | European Society for Blood and Marrow Transplantation | 126 | 2010-01-01 | 2021-10-14 |
| Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia Arsenic trioxide, Low-dose cytarabine alone - Acute Myeloid Leukemia | Phase 3 | Terminated | Cephalon | 67 | 2007-10-01 | 2012-08-01 |
| Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide conditioning for allogeneic HSCT - Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital Muenster | 30 | 2004-10-01 | 2012-12-18 |
| Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission Conditioning therapy - Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital Carl Gustav Carus | 198 | 2003-12-01 | 2013-06-20 |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Two post-remission strategies, Idarubicin versus daunorubicin - Acute Myeloid Leukemia | Phase 3 | Terminated | Acute Leukemia French Association | 465 | 1999-11-01 | 2008-02-21 |
Leukemia, Myeloid, Acute (17) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Recurrence (1)
Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Leukemia (17) · Leukemia, Myeloid (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Bone Marrow Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Disease Attributes (1) · Neoplasms by Site (1) · Pathologic Processes (1)
Azacitidine (4) · Cytarabine (3) · Cyclophosphamide (2) · Sodium Chloride (2) · Stem Cell Transplantation (2) · magrolimab (2) · venetoclax (2) · AP 1903 reagent (1) · Arsenic Trioxide (1) · Behavior Therapy (1) · Bone Marrow Transplantation (1) · Daunorubicin (1) · Decitabine (1) · Drug Therapy (1) · Idarubicin (1)
Gilead Sciences (2) · Acute Leukemia French Association (1) · Bellicum Pharmaceuticals (1) · Cephalon (1) · European Society for Blood and Marrow Transplantation (1) · GlycoMimetics Incorporated (1) · Helsinn Healthcare SA (1) · Jazz Pharmaceuticals (1) · Kiadis Pharma (1) · Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Seagen Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University Hospital Carl Gustav Carus (1) · University Hospital Heidelberg (1) · University Hospital Muenster (1)
United States (11) · Germany (10) · France (8) · Australia (6) · Italy (6) · Spain (6) · United Kingdom (6) · Austria (5) · Belgium (5) · Canada (5) · Netherlands (4) · Czechia (3) · Hungary (3) · Israel (3) · Poland (3)
Daniel J DeAngelo, MD, PhD (1) · Denis Claude Roy, Prof MD (1) · Dietger Niederwieser, Prof (1) · Gerhard Ehninger, MD (1) · Guillermo Garcia-Manero, MD (1) · Herve Dombret, M.D. (1) · Margaret Showel, MD (1) · Matthias Stelljes, M.D. (1) · Phoenix Ho, MD (1) · Stephan Mielke, Prof MD (1)
PMID 37703506, PMID 18838471, PMID 21459791, PMID 22959335, PMID 23248249, PMID 23749683, PMID 29550384, PMID 34732236, PMID 40009500, PMID 40233321
2015 (1), 2016 (1)